Rajshekhar Chakraborty, MD, Columbia University Irving Medical Center, New York, New York, discusses results from the LINKER-MM2 trial which evaluated the preliminary efficacy and safety of treatment with linvoseltamab plus carfilzomib among patients with relapsed/refractory (R/R) multiple myeloma (MM) who had received 3 or more prior lines of therapy (LoT).

The results of this analysis demonstrated deep and durable responses among patients with R/R MM who were triple-class exposed. Dr Chakraborty stated, “Overall, I think the safety and efficacy data are definitely very encouraging.”

Transcript:

Hi, I am Dr Rajshekhar Chakraborty from Columbia University in New York, and I'm here at ASCO 2025 and excited to present the safety and efficacy data of linvoseltamab in combination with carfilzomib in patients with relapsed/refractory multiple myeloma as a part of the LINKER-MM2 trial.

Some of the key highlights of this trial, I will focus on 3 bullet points. First, is the safety given it is a phase 1 trial. At a median follow-up of about 14.8 months, so roughly over a year, we saw that overall, this combination regimen, the toxicity was expected based on what we would anticipate from the individual toxicity profiles of these drugs. There was only 1 dose limiting toxicity, which was grade 4 thrombocytopenia in the setting of tumor lysis syndrome.

The most common treatment-emergent adverse events were CRS, neutropenia, and infection. Just to go into a little bit of detail into each of them. With CRS, cytokine release syndrome, all of them were grade 1 or grade 2. We did not see any grade 3 or higher CRS. Regarding neutropenia. The rate was about 56%, grade 3 or higher neutropenia. Regarding infections, overall infection rate was about 91% with the grade 3 or higher infection rate being about 43% roughly.

Now focusing on the efficacy, we saw a really high overall response rate, 90%, but I think what was even more interesting to me was the complete response or better of about 76%. A very high complete response rate as well. The responses were durable. At 1 year, the duration of response was about 87%, and the 1-year PFS was about 83%.

Overall, I think the safety and efficacy data are definitely very encouraging. Currently, a dose expansion cohort with this combination regimen is being planned and as well as a phase 3 randomized control trial comparing this regimen to the standard of care, anti-myeloma agents like the triplet regimens are also being planned and we will see how those pan out.

Source:

Manier S, Ocio E, Martinez-Chamorro C, et al. Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract 7513.